Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

The goal is the development of a lateral flow test for early disease detection

23 Feb 2024
Lawrence Howes
Editorial Assistant

Industry news

Tecan logo

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease.

This latest phase involves the development of an additional Optimer binder against the innovative Neuro-Bio target implicated in Alzheimer’s disease, with the goal of developing reagents for a lateral flow test for early disease detection. Following the earlier identification of Optimer binders to this novel Alzheimer’s disease biomarker, these binders have been characterized for use in lateral flow and biosensor assays.

Common lateral flow test formats require a pair of binders to increase diagnostic test accuracy. To prevent the need for animal-derived antibodies in its Alzheimer’s disease diagnostic, Neuro-Bio now requires the development of additional binders to support the lateral flow test format and deliver a wholly Optimer-powered test. As Optimer binders are oligonucleotide-based, rather than protein-based like antibodies, they offer further advantages including scalability of manufacture, improved shelf-life, and tuneability benefits that will allow more stable and specific reagents for use in lateral flow tests.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

BiosensorsBiosensors are devices used to detect an analyte using biological molecules specific to the analyte coupled to a detector. Biosensor instruments may be photometric, typically using surface plasma resonance (SPR), electrochemical or QCM (quartz crystal microbalance) biosensors. Biosensors should be selective, portable, robust and sensitive and have a fast response time. Systems may be manual or automated and usually have associated software.Cell Adhesion AssaysCell adhesion assays are used to quantitate attachment and analyze the molecular mechanisms for extracellular matrix adhesion, cell migration and sensitivity to inhibitors. Find the best cell adhesion assay equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :NeuroscienceNeuroscience research investigates the neurological mechanisms underlying behavior, neurodegenerative diseases, and other brain conditions. Learn about the innovative technologies for bioimaging, electrophysiology, cell culture, chromatography and other techniques used in this field.Alzheimers ResearchAlzheimer�s disease is a neurodegenerative condition characterized by progressive memory loss and cognitive decline. Research focuses on understanding the molecular and cellular mechanisms of the disease, as well as developing effective treatments and diagnostic tools. Browse our peer-reviewed product directory to find the best Alzheimer�s research products, compare options, check reviews, and get pricing directly from manufacturers.Assay DevelopmentThe process of proving an assay to be sensitive with respect to the target is known as assay development. The assay should be able to characterize novel compounds and measure the potency of these compounds against a validated biological target.NeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.
Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development